501 related articles for article (PubMed ID: 15064752)
1. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation.
Dhar A; Hu J; Reeves R; Resar LM; Colburn NH
Oncogene; 2004 May; 23(25):4466-76. PubMed ID: 15064752
[TBL] [Abstract][Full Text] [Related]
2. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.
Watts RG; Huang C; Young MR; Li JJ; Dong Z; Pennie WD; Colburn NH
Oncogene; 1998 Dec; 17(26):3493-8. PubMed ID: 10030673
[TBL] [Abstract][Full Text] [Related]
3. Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation.
Jansen AP; Colburn NH; Verma AK
Oncogene; 1999 Oct; 18(42):5806-13. PubMed ID: 10523861
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element.
Li JJ; Dong Z; Dawson MI; Colburn NH
Cancer Res; 1996 Feb; 56(3):483-9. PubMed ID: 8564958
[TBL] [Abstract][Full Text] [Related]
5. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
6. Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.
Matthews CP; Birkholz AM; Baker AR; Perella CM; Beck GR; Young MR; Colburn NH
Cancer Res; 2007 Mar; 67(6):2430-8. PubMed ID: 17363560
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
Chun KS; Kim SH; Song YS; Surh YJ
Carcinogenesis; 2004 May; 25(5):713-22. PubMed ID: 14729583
[TBL] [Abstract][Full Text] [Related]
8. Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model.
Cooper SJ; MacGowan J; Ranger-Moore J; Young MR; Colburn NH; Bowden GT
Mol Cancer Res; 2003 Sep; 1(11):848-54. PubMed ID: 14517347
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity.
Kim G; Khanal P; Lim SC; Yun HJ; Ahn SG; Ki SH; Choi HS
Carcinogenesis; 2013 Feb; 34(2):341-50. PubMed ID: 23125217
[TBL] [Abstract][Full Text] [Related]
10. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine.
Fan M; Goodwin ME; Birrer MJ; Chambers TC
Cancer Res; 2001 Jun; 61(11):4450-8. PubMed ID: 11389075
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response.
Li JJ; Westergaard C; Ghosh P; Colburn NH
Cancer Res; 1997 Aug; 57(16):3569-76. PubMed ID: 9270030
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells.
Chang PL; Cao M; Hicks P
Carcinogenesis; 2003 Nov; 24(11):1749-58. PubMed ID: 12919959
[TBL] [Abstract][Full Text] [Related]
13. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
Suzukawa K; Colburn NH
Oncogene; 2002 Mar; 21(14):2181-90. PubMed ID: 11948401
[TBL] [Abstract][Full Text] [Related]
14. Organ-specific activation of activator protein-1 in transgenic mice by 12-o-tetradecanoylphorbol-13-acetate with different administration methods.
Zhong S; Quealy JA; Bode AM; Nomura M; Kaji A; Ma WY; Dong Z
Cancer Res; 2001 May; 61(10):4084-91. PubMed ID: 11358830
[TBL] [Abstract][Full Text] [Related]
15. A JNK1/AP-1-dependent, COX-2 induction is implicated in 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation through regulating cell cycle progression.
Zhang D; Li J; Song L; Ouyang W; Gao J; Huang C
Mol Cancer Res; 2008 Jan; 6(1):165-74. PubMed ID: 18234971
[TBL] [Abstract][Full Text] [Related]
16. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion.
Young MR; Li JJ; Rincón M; Flavell RA; Sathyanarayana BK; Hunziker R; Colburn N
Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9827-32. PubMed ID: 10449779
[TBL] [Abstract][Full Text] [Related]
17. Differentiation-associated genes regulated by TPA-induced c-Jun expression via a PKC/JNK pathway in KYSE450 cells.
Yu X; Luo A; Zhou C; Ding F; Wu M; Zhan Q; Liu Z
Biochem Biophys Res Commun; 2006 Mar; 342(1):286-92. PubMed ID: 16480952
[TBL] [Abstract][Full Text] [Related]
18. Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells.
Kim JE; Son JE; Jang YJ; Lee DE; Kang NJ; Jung SK; Heo YS; Lee KW; Lee HJ
J Pharmacol Exp Ther; 2011 Sep; 338(3):1013-22. PubMed ID: 21705614
[TBL] [Abstract][Full Text] [Related]
19. Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line.
Liu G; Bode A; Ma WY; Sang S; Ho CT; Dong Z
Cancer Res; 2001 Aug; 61(15):5749-56. PubMed ID: 11479211
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model.
Zhao Y; Xue Y; Oberley TD; Kiningham KK; Lin SM; Yen HC; Majima H; Hines J; St Clair D
Cancer Res; 2001 Aug; 61(16):6082-8. PubMed ID: 11507057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
